Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing complete clinical response but only 20% complete imaging response at month 12. Clinical implications of these persistent imaging findings need clarification @RheumNow #EULAR2022 POS0804 https://t.co/sNbRzIkwnt

#EULAR2022 "The mRNA vaccines are simple to make." - Saul Faust The key step is encapsulation in lipid to allow for take up by cell. 💉💉💉 @RheumNow https://t.co/T2ZxF6bLV5

Comorbidity in AS from @rheum_cat , Karmacharya et al. Clustering of comorbidities. Depression and hypertension clusters assoc worse disease activity and function @RheumNow #EULAR2022 OP0154 https://t.co/jGQXayAYs9 https://t.co/SnVDhVYQq5

#EULAR2022 OP0134: Active RA increases risk of dementia Olmsted County, MINN studying RA risk factors for dementia: ⭐️886 pts incident RA, mean age 65. 103 develop dementia Risk factors: Age, rheum nodules, large jt swelling, depression/anxiety, HTN, CVD events @Rheumnow https://t.co/bUFkzBovAy

Fonzetti et al. Isolated Ro-52 in pSS. 300 patients. Less inflammatory features but more fibrotic disease - ILD and PBC. @RheumNow #EULAR2022 OP0146 https://t.co/2WIAu8qKiH https://t.co/mspSBNxbx2

Prof T Dorner summarizes what's new in #SLE #EULAR2022 @rheumnow https://t.co/YT0Ocw7I41

Large collaborative study on IIM treatment patterns from @Nellziade @ElenaNikiUK @LatikaGupta_ @drhectorchinoy @MarcinMilchert and many others. Significant geographic differences, highlighting need for consensus guidelines @RheumNow #EULAR2022 OP0161 https://t.co/osaORtgvxh https://t.co/96PypMtlcl

#EULAR2022 OP0138: BIOBADASER registry: Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior malignancy ⭐️352 pts w prior malignancy in registry, 32 developed a 2nd incident malignancy 27 rate of cancer/1000 patient years. No diff of cancer or mortality b/w Rx @Rheumnow https://t.co/nTuUooBmzV

Ghalandari et al EUDRAVIGILANCE database congenital malformations for non-TNFi bDMARDs (vs certolizumab). ORs suggest possible B-cell modulators and vedolizumab, not others. Geneticist rvw no pattern for B-cell agents. @RheumNow #EULAR2022 OP0129 https://t.co/nrj8MxjAri https://t.co/p6JkfjjtdH

Interestingly, anti-IFN Ab can be present in #SLE pts and impact the IFN signature. There is a bimodal type I IFN signature in #SLE. IFN and Blys signatures overlap (?distinct populations/interactions between the two?) - Prof T Dorner #EULAR2022 @rheumnow https://t.co/phLXv2KVxR

All the domains of sexual sphere are deteriorated in RA and PsA. This aspect is often overlooked and can have a significant impact on pts QoL. It may be time to assess this aspect more specifically using CSFQ-14 and propose dedicated interventions. #OP0139 @RheumNow #EULAR2022 https://t.co/l0zyBIZ1LI